Clinical Trials on Recurrent Ovarian Epithelial Cancer in Ireland

Total 469 results

Tesaro, Inc.
Myriad Genetics, Inc.; Facing Our Risk of Cancer Empowered

Completed

A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (QUADRA)

Ovarian Neoplasms | Ovarian Cancer

United States, Canada
Laekna Limited

Active, not recruiting

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian (PROFECTA-II)

Platinum-resistant Ovarian Cancer

United States, China
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Ovarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube High Grade Serous Adenocarcinoma | Primary Peritoneal Endometrioid Adenocarcinoma | Stage III Fallopian... and other conditions

United States
The Netherlands Cancer Institute

Recruiting

Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (OVHIPEC-2)

Ovarian Cancer

Netherlands, United States, France, Denmark, Italy, Sweden, Ireland
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass

Ovarian Cancer | Fallopian Tube Cancer

United States
Unither Pharmaceuticals

Terminated

Clinical Trial for Ovarian Cancer (OvaRex®)

Ovarian Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy

Fallopian Tube Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Malignant Ovarian Brenner Tumor and other conditions

United States
Amgen

Terminated

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Austria, Belgium, Italy, Netherlands, Spain, Canada, Denmark, Germany, Korea, Republic of, Russian Federation, Hong Kong, Greece, Japan
Oblato, Inc.

Active, not recruiting

Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

Recurrent Malignant Glioma | Brain Glioblastoma

United States
NCIC Clinical Trials Group

Completed

ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer

Ovarian Cancer

United States, Canada, United Kingdom
ImmunoGen, Inc.

Active, not recruiting

IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Ovarian Cancer

United States, United Kingdom, Belgium, Spain, Canada, Georgia
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Mucinous... and other conditions

United States, Korea, Republic of, Japan
Eli Lilly and Company

Completed

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

Ovarian Cancer

United States, Israel, Spain, Korea, Republic of, Australia, Belgium, United Kingdom, Italy
Menarini Group

Terminated

Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients (MIMOSA)

Ovarian Cancer

United States, Spain, Germany, Belgium, France, Czech Republic, Hungary, Italy, Poland
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Carcinoma | Ovarian Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell... and other conditions

United States
Pfizer

Terminated

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

Ovarian Cancer

United States, Canada, United Kingdom, Korea, Republic of, Netherlands, Hong Kong, Singapore, Ireland, Estonia, Japan, Taiwan, Italy, Turkey, Slovakia, Germany, Poland, Switzerland, Croatia, Hungary, Bulgaria, Latvia, Mexico, Romania, Russian Federation and more
Hoffmann-La Roche

Completed

A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer

Ovarian Cancer

France, Spain, Sweden, Hong Kong, Canada, Switzerland, Estonia, Greece, Russian Federation, Hungary, Austria, Bulgaria, Netherlands, Latvia, Italy, Slovenia, Turkey, Serbia, Israel, Argentina, Brazil, Slovakia, Lithuania, Poland, Portugal, Mexi... and more
St. James's Hospital, Ireland
Karolinska Institutet; St Mary's Hospital, Paddington, London

Completed

European iNvestigation of SUrveillance After Resection for Esophageal Cancer (ENSURE)

Esophageal Cancer | Chemoradiation | Chemotherapy | Surgery | Metastatic Cancer | Radiation | Recurrent Esophageal Cancer

Sweden, Ireland, United Kingdom
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

Pain | Neuropathy | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian Cancer | Stage IIIB Primary Peritoneal Cancer | Stage IIIC Fallopian Tube Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Primary... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous... and other conditions

United States, Korea, Republic of, Canada, Japan
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Gliosarcoma | Recurrent Glioblastoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
Canadian Cancer Trials Group
National Cancer Institute (NCI); Cancer Research UK; Grupo Español de Investigación... and other collaborators

Completed

Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer | Metastatic Cancer

Canada, Spain, United States, United Kingdom
National Cancer Institute (NCI)
NRG Oncology

Completed

Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Carcinoma | Stage IIIA Uterine Corpus Cancer | Stage IIIB Uterine Corpus Cancer | Stage IVA Uterine Corpus Cancer | Stage IVB Uterine Corpus Cancer | Stage IIIC1 Uterine Corpus Cancer | Stage IIIC2 Uterine Corpus Cancer

United States
Tesaro, Inc.
European Network of Gynaecological Oncological Trial Groups (ENGOT); US Oncology... and other collaborators

Completed

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Ovarian Neoplasms | Platinum Sensitive Ovarian Cancer

United States, Belgium, Sweden, Germany, Israel, Austria, Canada, Denmark, Spain, Italy, United Kingdom, Poland, France, Hungary, Norway
zr Pharma & GmbH
Foundation Medicine; Myriad Genetics, Inc.

Completed

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) (ARIEL3)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Spain, Belgium, Australia, Israel, Germany, France, United Kingdom, Italy, Canada, New Zealand
Pfizer

Terminated

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

Low-grade Serous Ovarian Cancer | Low-grade Serous Fallopian Tube Cancer | Low-grade Serous Peritoneal Cancer

United States, Canada, Hungary, Spain, Belgium, France, United Kingdom, Australia, Czechia, Netherlands, Sweden, Italy, Denmark, Germany, Austria, Finland, Ireland, Norway, Poland
ppharmaand GmbH
Bristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological... and other collaborators

Active, not recruiting

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response

United States, United Kingdom, Korea, Republic of, Russian Federation, Canada, Denmark, Taiwan, New Zealand, Ireland, Japan, Spain, Australia, Israel, Italy, Greece, Sweden, Czechia, Finland, Poland, Belgium, Germany, Romania, Singa... and more
Acrivon Therapeutics
GOG Foundation

Recruiting

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Platinum-resistant Ovarian Cancer | Urothelial Carcinoma | Endometrial Adenocarcinoma

United States
Aravive, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Terminated

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)

Platinum-resistant Ovarian Cancer

United States, Spain, Belgium, Canada, Georgia, Czechia, China, Poland, France, United Kingdom, Italy
Morphotek
Eisai Europe Ltd. (United Kingdom)

Terminated

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Ovarian Cancer

United States, Hong Kong, Netherlands, Spain, Korea, Republic of, Belgium, Taiwan, Israel, Japan, France, United Kingdom, Singapore, Italy, Argentina, India, Germany, Hungary, Australia, Portugal, Russian Federation, Canada, Poland, Greec... and more
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer AJCC v8 | Stage II Fallopian Tube Cancer AJCC v8 | Stage II Ovarian... and other conditions

United States, Canada, Korea, Republic of, Puerto Rico, Ireland
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation | Endometrioid Stromal Sarcoma

United States
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid... and other conditions

United States, Puerto Rico
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States, Colombia, Mexico, Chile
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma and other conditions

United States, Korea, Republic of, Canada
Tesaro, Inc.
Gynecologic Oncology Group; European Network of Gynaecological Oncological... and other collaborators

Active, not recruiting

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Ovarian Neoplasms

United States, Spain, Finland, Czechia, Italy, Denmark, Germany, Belgium, Israel, Canada, Russian Federation, Sweden, United Kingdom, Poland, Ireland, Ukraine, France, Norway, Switzerland, Hungary
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer

Recurrent Uterine Corpus Sarcoma | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Recurrent Cervical Carcinoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma | Stage I Uterine... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Endometrial Carcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Agenus Inc.

Terminated

Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

Gliosarcoma | Recurrent Glioblastoma | Recurrent Adult Brain Tumor

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Lung Adenocarcinoma | Recurrent Lung Non-Small Cell Carcinoma | Recurrent Lung Adenocarcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
AstraZeneca
Merck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Advanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum Chemotherapy

Korea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain
Bristol-Myers Squibb

Active, not recruiting

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

Australia, Russian Federation, United States, Argentina, Austria, Belgium, Brazil, Chile, France, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Romania, Spain, Switzerland, United Kingdom
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma and other conditions

United States
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

United Kingdom, Korea, Republic of, Australia, United States, Spain

Clinical Trials on Recurrent Ovarian Epithelial Cancer in Ireland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations